

Drug Pipeline 2026-2027

Brittany Karas, PharmD, BCPS

Medication-Use Policy Program Manager, Northwestern Medicine

Rachel Joseph, PharmD, BCPS

Clinical Manager, Specialty Pharmacy, Northwestern Medicine



2026 ICHP Annual Meeting

Statement of Disclosure

- The speakers have no conflicts of interest with ineligible companies to disclose




Learning Objectives

- Outline the FDA drug approval pathway, including expedited review programs and PDUFA target action dates.
- Describe recent FDA changes in clinical trial design, including single pivotal trial and real-time clinical trials.
- Identify emerging therapies with anticipated FDA approval over the next 12 months and discuss their novel mechanisms of action.
- Review efficacy, safety, and therapeutic niche of selected pipeline agents expected to impact acute care, specialty, and infusion pharmacy services.



FDA Approval pathway



2026 ICHP Annual Meeting

Lolic M. Food & Drug Administration (FDA). NDA at the FDA. Accessed August 14, 2026.

FDA Drug Development Designations

Development



Fast Track

- Treats a serious condition and fills an unmet need
- Frequent FDA meetings; eligible for accelerated and priority review

Breakthrough Therapy

- A serious condition and preliminary clinical evidence of **substantial** improvement
- All fast track features plus intensive guidance and organizational commitment

Review



Priority Review

- Directs FDA attention and resources to drugs offering significant improvement
- Action within 6 months versus 10 months for standard review

Approval



Accelerated Approval

- Surrogate endpoints reasonably likely to predict benefit can support approval
- Confirmatory phase 4 trials required after approval

A single drug may carry more than one designation.

US Food & Drug Administration. Development & Approval Process (Drugs). Accessed August 12, 2026.



2026 ICHP Annual Meeting

Commissioner's National Priority Voucher Pilot Program

CNPV Program at a glance

- Ultra-accelerated priority review using a collaborative, tumor board-style review process
- Prioritizes review of products that align with strategic national importance

Presubmission requirements



- Sponsors engage the FDA and submit key materials before filing
- Front-loading the package makes the compressed timeline possible

Review in 1 to 2 months



- Target 1 to 2 months vs 6 months
- A multidisciplinary team reviews together rather than sequentially

National priority alignment




- Public health crises
- Breakthrough innovation
- Unmet need
- Onshoring of manufacturing
- Affordability of the product

US Food & Drug Administration. Commissioner's National Priority Voucher (CNPV) Pilot Program. Accessed August 12, 2026.



2026 ICHP Annual Meeting

Prescription Drug User Fee Act (PDUFA)



The “PDUFA date”

The goal date by which the FDA aims to act on an application, set when it is filed

Sibbesen JB, Rich J. Understanding the FDA Approval Process and PDUFA Dates.. Accessed August 12, 2026.



2026 ICHP Annual Meeting

Knowledge Check 1

A drug for a serious condition is approved on a surrogate endpoint reasonably likely to predict clinical benefit, with a confirmatory trial required after approval. Which program best fits with this definition?

- A. Accelerated Approval
- B. Priority Review
- C. Fast Track Designation
- D. Breakthrough Therapy Designation



2026 ICHP Annual Meeting

Recent FDA Updates – Single Pivotal Trial

- Historically 2 positive pivotal trials were expected to establish substantial evidence
- 2026 Approach: one trial plus confirmatory evidence



The evidentiary standard is unchanged — the path to meeting it is more flexible


Prasad V, Makary MA. N Engl Med. 2026



2026 ICHP Annual Meeting

Prior to Single Pivotal Trial Model

>50% of drug approvals rested on a single pivotal trial



Godoy et al. Clinical Trials. 2025

Real-Time Clinical Trials (RCT)

FDA initiative: predefined safety and efficacy data reach the agency while the trial is running

STANDARD TRIAL

- ▶ Sites collect data throughout the study, held internally
- ▶ Results packaged at set intervals
- ▶ FDA sees the evidence in one batch at submission
- ▶ Review clock starts once the full package arrives

REAL-TIME TRIAL

- ▶ AI-enabled feeds transmit agreed upon endpoint signals
- ▶ FDA continuously reviews safety and efficacy
- ▶ Issues surface early, not at submission
- ▶ Potential for faster decision-making

Two proof-of-concept trials are now underway to test the real-time model

Logan M. BMJ. 2026.



2026 ICHP Annual Meeting

Knowledge Check 2

Under the FDA's single pivotal trial approach, which statement correctly describes what is required to establish substantial evidence of effectiveness?

- A. One adequate and well-controlled trial alone, with the evidentiary standard lowered
- B. One trial with a surrogate endpoint, with no post-approval obligations
- C. One adequate and well-controlled trial plus confirmatory evidence, meeting the same substantial evidence standard
- D. Two adequate and well-controlled trials, as has always been required



2026 ICHP Annual Meeting

Symbols



Oral therapy



Injectable



Infusion



Topical



Cell or Gene Therapy



Ophthalmic



Specialty Pharmacy



Hospital or Clinic
Administered



Self-administered



2026 ICHP Annual Meeting

Select 2026 + 2027 Pipeline Agents

Anitocabtagene Autoleucel	Asundexian	Bepirovirsen	Bictegravir; lenacapavir	Cagrilintide/ semaglutide
Denecimig	Giredestrant	Ianalumab	Ifinatamab	Imsidolimab
Insulin Efsitora Alfa	Lirafugratinib	Neladalkib	Ozekibart	Pelacarsen
Povorcitinib	Pritelivir	Rebisufligene Etisparvovec	Varegacestat	Zipalertinib

Brand and Biosimilar Pipeline Database [proprietary data]. IPD Analytics; 2026.



2026 ICHP Annual Meeting

Lirafugratinib



Anticipated Place in Therapy

- Second line option for pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements
- First highly selective, irreversible FGFR2 inhibitor
- FDA PDUFA date = September 27, 2026

Mechanism of Action

- FGFR2 tyrosine kinase inhibitor - blocks FGFR2 signaling pathway

Important Trials

- ReFOCUS Cohort: patients with FGFR inhibitor-naïve CCA
- ORR 46.5% (95% CI, 37.1%-56.1%)

Dosing and Administration

- 70 mg once daily orally

Hollebecque A. J Clin Oncol 44, 2026



2026 ICHP Annual Meeting

Giredestrant



Anticipated Place in Therapy

- New generation selective estrogen receptor degrader (SERD)
- Significant advancement in adjuvant endocrine therapy in ~20 years
- FDA PDUFA Date = November 30, 2026

Mechanism of Action

- Blocks oestrogen from binding to the receptor triggering the breakdown (degradation) and stopping/slowing growth

Important Trials

- Phase III evERA Breast Cancer study: everolimus with giredestrant or SOC endocrine therapy
- Reduced risk of invasive disease recurrence or death by 30% vs SOC endocrine therapy/everolimus (HR=0.70, 95%CI 0.57-0.87).

Dosing and Administration

- 30 mg orally once daily

Joseph R, et al. Am J Health Syst Pharm. 2026.
Roche. FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting. Accessed August 12, 2026.



2026 ICHP Annual Meeting



Ifinatomab deruxtecan

Anticipated Place in Therapy

- Adult patients with extensive-stage small cell lung cancer with disease progression or after platinum-based chemotherapy
- FDA PDUFA Date = October 10, 2026

Important Trials

- Phase 2 IDEate-Lung01 Trial
- ORR 48.2% - median duration 5.3 months
- 9-month overall survival ~59.1%

Mechanism of Action

- First-in-class B7-H3 directed antibody drug conjugate

Dosing and Administration

- 12 mg/kg IV every 3 weeks

Merck. Ifinatomab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer. Accessed August 12, 2026.

1. Martin C. International Association for the Study of Lung Cancer. Accessed August 12, 2026.



2026 ICHP Annual Meeting

Neladalkib



Anticipated Place in Therapy

- NSCLC with diverse ALK fusions and resistance mutations
- A “4th generation” ALK inhibitor for previously treated disease
- FDA PDUFA date = November 27, 2026

Mechanism of Action

- Brain-penetrant, ALK-selective tyrosine kinase inhibitor
- Designed to cover diverse ALK fusions and resistance mutations

Important Trials

- ALKOVE-1 (phase I/II) in advanced ALK-positive NSCLC
- ORR 31% after prior ALK TKI therapy; ORR 86% in TKI-naïve patients

Dosing and Administration

- 150 mg daily orally

Lin JJ et al. J Clin Oncol. 2026
Doherty K. OncoLive. FDA Grants Priority Review to Neladalkib for TKI-Pretreated ALK+ NSCLC. Accessed August 12, 2026.



2026 ICHP Annual Meeting

Zipalertinib



Anticipated Place in Therapy

- Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations
- Post-platinum, with or without prior amivantamab; an oral option where targeted choices are limited
- FDA PDUFA date = February 27, 2027

Mechanism of Action

- Oral, next-generation irreversible EGFR tyrosine kinase inhibitor
- Targets exon 20 insertion and other activating EGFR variants while sparing wild-type EGFR

Important Trials

- REZILIENT1 (phase 2b): zipalertinib monotherapy after prior systemic therapy; primary endpoint ORR
- Confirmed ORR 35% (n=176), median DOR 8.8 months; ORR 40% after platinum only (n=125)

Dosing and Administration

- 100 mg orally twice daily

Doherty K, Mackay K. OncLive.FDA Accepts NDA for Zipalertinib in Locally Advanced or Metastatic EGFR Exon 20+ NSCLC. Accessed August 12, 2026.



2026 ICHP Annual Meeting



Ozekibart

Anticipated Place in Therapy

- Adults with unresectable or metastatic grade 2 or 3 conventional chondrosarcoma
- Would be first and only FDA approved treatment
- FDA PDUFA date = April 14, 2027

Mechanism of Action

- Precision-engineered tetravalent death receptor 5 (DR5) agonist antibody
- Clusters and activates DR5 to trigger tumor cell apoptosis without requiring Fc crosslinking

Important Trials

- ConDRAGON (phase 3) in inoperable or metastatic conventional chondrosarcoma
- Improved PFS: 5.52 months vs 2.66 months (HR 0.479; 95% CI 0.33-0.68; $p < 0.0001$)

Dosing and Administration

- 3 mg/kg IV every 3 weeks

Inhibrx. Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma. Accessed August 12, 2026.



2026 ICHP Annual Meeting

Varegacestat



Anticipated Place in Therapy

- Adults with desmoid tumors
- An option for a rare soft tissue tumor with limited systemic therapies – potential to be SOC
- FDA PDUFA Date = April 28, 2027

Mechanism of Action

- Gamma-secretase inhibitor (GSI)
- Blocks notch signaling implicated in desmoid tumor growth

Important Trials

- RINGSIDE trial in adults with progressing desmoid tumors
- PFS HR 0.16 (95% CI 0.071-0.375; $p < 0.0001$), an 84% reduction in progression or death; confirmed ORR 56% vs 9%

Dosing and Administration

- 1.2 mg once daily

Ryan C. Onclive. Varegacestat Represents Potential SOC for Progressing Desmoid Tumors. Accessed August 12, 2026.



2026 ICHP Annual Meeting

Novel Therapy Approvals?

Therapy	Indication
Daraxonrasib	Pancreatic cancer
Vusolimogene oderparepvec	Melanoma
Deramiocecl	Cardiomyopathy associated with Duchenne muscular dystrophy
Pariglasgene breccaparvovec	Von Gierke disease (glycogen storage disease type I)



2026 ICHP Annual Meeting

Rebisufligene Etisparvovec



Anticipated Place in Therapy

- Treatment of Sanfilippo syndrome Type A (MPS IIIA)
- Potential first disease-modifying therapy
- FDA PDUFA Date = September 19, 2026

Important Trials

- Data reduced levels of CSF-HS (heparan sulfate) within first month
- Median reduction in CSF-HS was 63.98%

Mechanism of Action

- In vivo AAV9 gene therapy
- Delivers a healthy copy of the SGSH gene

Dosing and Administration

- One time IV infusion

Ultragenyx. Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results. Accessed August 12, 2026.



2026 ICHP Annual Meeting

Anitocabtagene Autoleucel



Anticipated Place in Therapy

- Multiple myeloma
- FDA PDUFA date December 23, 2026

Important Trials

- Phase 2 iMMagine-1 study
- 74% achieve stringent CR or CR
- OS rates 94% at 12 months, 88% at 18 months, 83% at 24 months

Mechanism of Action

- BCMA-directed CAR T-cell therapy
- D-domain technology → reduce toxicities

Dosing and Administration

- IV infusion – single dose in phase 2

Gilead. Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Accessed August 12, 2026.



2026 ICHP Annual Meeting

Bepirovirsen



Anticipated Place in Therapy

- First line for chronic hepatitis B infection along with nucleotide analog (NA) therapy

FDA PDUFA date October 26, 2026

Mechanism of Action

- Antisense oligonucleotide that recruits liver enzymes to degrade hepatitis B RNA thereby reducing viral replication and production of HBV antigens

Important Trials

- B-WELL-1 and B-WELL-2
 - Bepirovirsen compared to placebo (in addition to SOC NA) showing functional cure in treatment arm in 19-20% of patients.

Dosing and Administration

- 300mg subcutaneously weekly for 6 months

Hou et al. NEJM. 2026



2026 ICHP Annual Meeting



Bictegravir; lenacapavir

Anticipated Place in Therapy

- HIV-1 treatment - single oral tablet regimen
- PDUFA date: August 27, 2026

Mechanism of Action

- Bictegravir: integrase strand-transfer inhibitor (INSTI) with high resistance barrier
- Lenacapavir: capsid inhibitor (first in class)

Important Trials

- ARTISTRY-1 and ARTISTRY-2 trials
- Non-inferiority to other multi-tablet HIV-1 treatment regimens
- Less complex oral option for treatment-experienced and treatment-naïve patients

Dosing and Administration

- Bictegravir 75 mg/lenacapavir 50 mg orally once daily

Orkin et al. The Lancet. 2026



2026 ICHP Annual Meeting

Pritelivir



Anticipated Place in Therapy

- Oral agent for treatment of HSV-1 in immunocompromised patient population, competing with currently available IV treatment options

Anticipated FDA approval late 2026

Mechanism of Action

- DNA-helicase primase inhibitor

Important Trials

- PRIOH-1: Phase 3 trial comparing pritelivir to the standard of care (SOC) in immunocompromised patients ≥ 16 years with refractory HSV infection with or without resistance to acyclovir or foscarnet
 - Met primary endpoint of lesion healing at 28 days in 62.7% of pritelivir compared to 34% of placebo patients

Dosing and Administration

- 400mg orally day 1, 100mg orally daily thereafter for 28 day course (in PRIOH-1 extended additional 14 days if necessary)

Papanicolaou et al. Transplantation and Cellular Therapy. 2026



2026 ICHP Annual Meeting

Povorcitinib



Anticipated Place in Therapy

- First oral targeted therapy for hidradenitis suppurativa (HS) competing with other biologics for moderate to severe HS
- In clinical development for nonsegmental vitiligo, prurigo nodularis, and asthma

FDA approval anticipated in 1Q 2027

Mechanism of Action

- Janus kinase (JAK) 1 Inhibitor

Important Trials

- STOP-HS1 and STOP-HS2
 - Phase 3 trials evaluating povorcitinib compared to placebo in adult patients with moderate to severe HS and inadequate response to $\geq$ oral antibiotic or biologic
 - Primary endpoint met of HS clinical response 50 (HiSCR50) compared to placebo at week 12 with increased response over time

Dosing and Administration

- 45 mg or 75mg orally daily

Porter et al. Nature. 2026



2026 ICHP Annual Meeting

Ianalumab



Anticipated Place in Therapy

- Breakthrough therapy designation - first targeted treatment for Sjögren's disease (SjD)
- Along with eltrombopag, short-course second-line therapy in immune thrombocytopenia (ITP)
- Estimated FDA approval in second half of 2026

Mechanism of Action

- Human IgG1 mAb that depletes B cells through enhanced antibody-dependent cellular cytotoxicity (ADCC)
- Also inhibits B-cell activation and survival via BAFF-R blockade

Important Trials

- NEPTUNUS-1 & NEPTUNUS-2: first replicate phase 3 studies showing statistically significant ESSDAI improvement vs placebo
- Ianalumab + eltrombopag in ITP: statistically significant increase in time to treatment failure vs placebo

Dosing and Administration

- SjD: 300 mg SC monthly vs every 3 months (NEPTUNUS-2: no statistically significant difference between groups)
- ITP: 3 mg/kg vs 9 mg/kg IV monthly x 4 months

Beck et al. American College of Rheumatology Conference. 2025.
Cuker et al. NEJM. 2025



2026 ICHP Annual Meeting

Imsidolimab



Anticipated Place in Therapy

- Targeted treatment for generalized pustular psoriasis (GPP) flares in competition with spesolimab
- FDA PDUFA date: December 12, 2026

Mechanism of Action

- Interleukin-36 receptor (IL-36R) antagonist

Important Trials

- GEMINI-1 and GEMINI-2
 - In GEMINI-1 one loading dose showed statistically significant improvement of GPP Physician Global Assessment (GPPPGA) score at week 4 compared to placebo
 - GEMINI-2 studied maintenance dosing showing patients on maintenance dosing remained with a GPPPGA score of 0/1 with no flares compared to placebo

Dosing and Administration

- Loading dose: 750mg IVPB x 1
- Maintenance dose: 200mg subcutaneously q4 weeks

Smieszek et al. NEJM. 2026



2026 ICHP Annual Meeting

Denecimig



Anticipated Place in Therapy

- Bleeding prophylaxis in adult and pediatric patients with hemophilia A, with or without factor VIII inhibitors
- FDA approval expected in the second half of 2026

Mechanism of Action

- Bispecific antibody mimicking activated factor VIII

Important Trials

- FRONTIER program; FRONTIER-4
- Denecimig prophylaxis superior to on-demand treatment in preventing bleeding events in hemophilia A

Dosing and Administration

- Tiered subcutaneous dosing by weight and frequency

		Maintenance dosing frequency		
		QM	Q2W	QW
Weight range	<15 kg	9 mg	4 mg	1.6 mg
	15–<45 kg	20 mg	9 mg	4 mg
	≥45 kg	46 mg	20 mg	9 mg

Q2W, once every 2 weeks; QM, once every month; QW, once every week.

Mancuso et al. NEJM. 2026



2026 ICHP Annual Meeting

Asundexian



Anticipated Place in Therapy

- First in class Factor XIa inhibitor for secondary prevention of non-cardioembolic ischemic stroke or transient ischemic attack

FDA approval expected in November 2026

Mechanism of Action

- Coagulation factor XIa (FXIa) inhibitor

Important Trials

- OCEANIC-STROKE: Phase 3 trial in patients post non-cardioembolic ischemic stroke or high-risk TIA taking standard antiplatelet therapy, ischemic stroke was reduced by 26% compared to placebo

Dosing and Administration

- 50mg orally once daily in addition to planned single or double anti-platelet therapy

Sharma et al. NEJM. 2026



2026 ICHP Annual Meeting

Pelacarsen



Anticipated Place in Therapy

- First in class agent targeting elevated Lp(a) for cardiovascular risk reduction, offering a treatment option for secondary prevention in patients with established CVD/ASCVD and elevated Lp(a)
 - Other agents with similar mechanisms currently entering phase 3 trials

Anticipated FDA approval in 2027 with granted fast-track status

Mechanism of Action

- Apolipoprotein(a) (Apo[a]) mRNA translation inhibitor

Important Trials

- Phase 2 dose finding study showed dose-dependent Lp(a) reductions of 35% to 80% compared to 6% with placebo – 20mg weekly having highest response
- Phase 3 Lp(a)HORIZON phase 3 trial ongoing

Dosing and Administration

- Anticipated to be 80mg subcutaneously every month based on phase 2 dose finding study (current dosing in Lp(a) HORIZON trial)

Cho et al. American Heart Journal. 2025



2026 ICHP Annual Meeting



Insulin Efsitora Alfa

Anticipated Place in Therapy

- Basal insulin for type 1 and type 2 diabetes mellitus
- Estimated FDA approval in second half of 2026

Mechanism of Action

- Fusion protein: single-chain insulin analog linked to the fragment crystallizable (Fc) domain of human immunoglobulin G2
- Results in more controlled glucose uptake and sustained insulin activity

Important Trials

- QWINT-1, QWINT-3 and QWINT-4 phase 3 clinical trials
- All three met the primary endpoint of non-inferior A1c reduction compared to daily basal insulin

Dosing and Administration

- Variable subcutaneous dosing based on glucose control, once weekly
- QWINT-1 used a fixed-dose regimen in insulin-naïve patients with only four titration options

Tran. Journal of Clinical Diabetes. 2025



2026 ICHP Annual Meeting

Cagrilintide/semaglutide



Anticipated Place in Therapy

- Novel amylin analog + GLP-1 RA therapy for weight loss
- Will likely have to compete amongst available GLP-1/GIP agents

Mechanism of Action

- Amylin analog and GLP-1 receptor agonist

Important Trials

- REDEFINE – 1: Showed >20% weight loss in patients in cagrilintide/semaglutide arm compared to placebo over 68 weeks
- REDEFINE – 4: compared directly to tirzepatide, patients on tirzepatide saw weight loss of 23.6% compared to those on cagrilintide/semaglutide of 20.2%

Dosing and Administration

- Variable titrated subcutaneous dosing starting at 2.4mg cagrilintide /2.4mg semaglutide weekly

Garvey et al. NEJM. 2025



2026 ICHP Annual Meeting

Knowledge Check 3

Which pipeline agent is a first-in-class Factor XIa inhibitor for secondary prevention of non-cardioembolic ischemic stroke or TIA?

- A. Asundexian
- B. Pelacarsen
- C. Denecimig
- D. Ianalumab



2026 ICHP Annual Meeting

Knowledge Check 4

Which agent is a precision-engineered tetravalent death receptor 5 (DR5) agonist antibody designed to trigger apoptosis in tumor cells?

- A. Varegacestat
- B. Neladalkib
- C. Ozekibart
- D. Ifinamab deruxtecan



2026 ICHP Annual Meeting

Summary

- Expedited review programs and the CNPV pilot are designed to shorten time to approval.
- New FDA programs (eg, single pivotal trial, real-time clinical trials) improve efficiency without changing the evidentiary standard.
- Emerging therapy approvals are expected over the next 12 months, many with first-in-class mechanisms.
- Anticipate formulary review, infusion capacity, and specialty onboarding needs for these niche therapies.



2026 ICHP Annual Meeting

References

- Lolic M. Food & Drug Administration (FDA). NDA at the FDA. Accessed August 14, 2026. <https://www.fda.gov/media/105012/download>.
- US Food & Drug Administration. Development & Approval Process (Drugs). Accessed August 12, 2026. <https://www.fda.gov/drugs/development-approval-process-drugs>.
- US Food & Drug Administration. Commissioner's National Priority Voucher (CNPV) Pilot Program. Date updated July 17, 2026. . Accessed August 12, 2026. <https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program>
- Sibbesen JB, Rich J. Understanding the FDA Approval Process and PDUFA Dates. Date published March 20, 2025. Accessed August 12, 2026. <https://www.pharmacytimes.com/view/understanding-the-fda-approval-process-and-pdufa-dates>.
- Prasad V, Makary MA. One pivotal trial, the new default option for FDA approval – Ending the two-trial dogma. N Engl Med 2026;394:815-817.
- Barile Godoy C, Ramachandran R, Sapre P, Ross JS. Clinical Trials. 2026;23(1):109-112.
- Logan M. US pushes real time clinical trials to eliminate “dead time” in approvals. BMJ. 2026;393:s855.
- Brand and Biosimilar Pipeline Database [proprietary data]. IPD Analytics; 2026. Accessed July 1, 2026.
- Hollebecque A. Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma (CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2 f/r). J Clin Oncol 44, 2026 (suppl 2; abstr 476)
- Merck. Ifinamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer. Published August 18, 2025. Accessed August 12, 2026.
- Martin C. International Association for the Study of Lung Cancer. Ifinamab Deruxtecan Demonstrates High Response Rate in Previously Treated Extensive-Stage Small Cell Lung Cancer: Phase 2 IDEate-Lung01 Trial. Published September 7, 2025. Accessed August 12, 2026.
- Joseph R, Sabbah M, Barada F, Sarnot K, Levitsky AM, Rim MH. Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027). Am J Health Syst Pharm. 2026 Jul 6:zxag179. doi: 10.1093/ajhp/zxag179. Online ahead of print.



2026 ICHP Annual Meeting

References

- Roche. FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting. Published June 1, 2026. Accessed August 12, 2026. <https://www.roche.com/media/releases/med-cor-2026-06-02>
- Lin JJ, Felip E, Chl Cho B, et al. ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC. J Clin Oncol. 2026;44:8503.
- Doherty K. OncLive. FDA Grants Priority Review to Neladalkib for TKI-Pretreated ALK+ NSCLC. Published May 27, 2026. Accessed August 12, 2026. <https://www.onclive.com/view/fda-grants-priority-review-to-neladalkib-for-tki-pretreated-alk-nsclc>
- Inhibrx. Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma. Published June 15, 2026. Accessed August 12, 2026. <https://inhibrxbiosciences.investorroom.com/2026-06-15-Inhibrx-Announces-U-S-FDA-Acceptance-of-BLA-for-Ozekibart-in-Patients-with-Conventional-Chondrosarcoma>
- Ryan C. OncLive. Vargacestat Represents Potential SOC for Progressing Desmoid Tumors. Published June 4, 2026. Accessed August 12, 2026. <https://www.onclive.com/view/vargacestat-represents-potential-soc-for-progressing-desmoid-tumors>
- Doherty K, Mackay K. OncLive. FDA Accepts NDA for Zipalertinib in Locally Advanced or Metastatic EGFR Exon 20+ NSCLC. Published April 28, 2026. Accessed August 12, 2026. <https://www.onclive.com/view/fda-accepts-nda-for-zipalertinib-in-locally-advanced-or-metastatic-egfr-exon-20-nsclc>
- Ultragenyx. Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA). Published February 3, 2026. Accessed August 12, 2026. <https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-positive-longer-term-data-demonstrating>
- Gilead. Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma. Published December 6, 2025. Accessed August 12, 2026. <https://www.gilead.com/news/news-details/2025/kite-announces-new-data-for-pivotal-immagine-1-study-at-ash-2025-highlighting-anito-cels-opportunity-in-relapsed-or-refractory-multiple-myeloma>
- Hou J, Lim SG, Buti M, et al; B-Well Study Group. Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection. N Engl J Med. Published online 2025. Accessed August 13, 2026. doi:10.1056/NEJMoa2515131. <https://www.nejm.org/doi/full/10.1056/NEJMoa2515131>



2026 ICHP Annual Meeting

References

- Papanicolaou GA, Avery RK, Workowski K, et al. Pritelivir demonstrated superior efficacy compared to investigator's choice treatment for refractory herpes simplex virus infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy. *Transplant Cell Ther.* 2026;32(3 Suppl):S18-S19.
- Porter ML, Martorell A, Sayed CJ, et al. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. *Nat Med.* Published online 2026. doi:10.1038/s41591-026-04534-z.
- Grader-Beck T, Mariette X, Finzel S, et al. Ianalumab demonstrates significant reduction in disease activity in patients with Sjogren's disease: efficacy and safety results from two global phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2). Abstract LB24. Presented at: ACR Convergence 2025. <https://acrabstracts.org/abstract/ianalumab-demonstrates-significant-reduction-in-disease-activity-in-patients-with-sjogrens-disease-efficacy-and-safety-results-from-two-global-phase-3-randomized-placebo-controlled-double-blind-s/> (accessed August 13, 2026)
- Cuker A, Stauch T, Cooper N, et al; VAYHIT2 Investigators. Ianalumab plus eltrombopag in immune thrombocytopenia. *N Engl J Med.* Published online 2025. doi:10.1056/NEJMoa2515168.
- Smieszek S, Przychodzen B, Tyner C, et al. Efficacy and safety of imsidolimab for generalized pustular psoriasis. *NEJM Evid.* Published online 2025.
- Mancuso ME, Chan AKC, Shanmukhaiah C, et al; FRONTIER2 Investigators. Mim8 bispecific antibody prophylaxis in hemophilia A with or without inhibitors. *N Engl J Med.* Published online 2025. doi:10.1056/NEJMoa2517384.
- Sharma M, Dong Q, Hirano T, et al; OCEANIC-STROKE Investigators. Asundexian for secondary stroke prevention. *N Engl J Med.* Published online 2025. doi:10.1056/NEJMoa2513880.
- Cho L, Nicholls SJ, Nordestgaard BG, et al. Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a). *Am Heart J.* Published online 2025.
- Tran E. Breaking the daily routine with insulin efsitora alfa, a once-weekly basal insulin. *Clin Diabetes.* 2025;43(4):607.
- Garvey WT, Bluher M, Osorto Contreras CK, et al; REDEFINE 1 Study Group. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. *N Engl J Med.* Published online 2025. doi:10.1056/NEJMoa2502081.



2026 ICHP Annual Meeting

Drug Pipeline 2026-2027

Brittany Karas, PharmD, BCPS

Medication-Use Policy Program Manager, Northwestern Medicine

Rachel Joseph, PharmD, BCPS

Clinical Manager, Specialty Pharmacy, Northwestern Medicine



2026 ICHP Annual Meeting